ABSTRACT
Objective In the United States, over 6 million patients are affected by Alzheimer’s Disease and Related Dementias (ADRD). The study aims to develop and validate machine learning (ML) models for the early diagnosis and prediction of ADRD using de-identified Electronic Health Record (EHR) data from the University of Missouri (MU) Healthcare for different prediction windows.
Materials and Methods The study used de-identified EHR data provided by the MU NextGen Biomedical Informatics (BMI). An initial cohort of 380,269 patients aged over 40 with at least two healthcare encounters was narrowed to a final dataset of 4,012 unique patients of ADRD cases and 119,723 unique patients of controls. We trained and evaluated six different ML classifier models: Gradient-Boosted Trees (GBT), Light Gradient-Boosting Machine (LightGBM), Random Forest (RF), eXtreme Gradient-Boosting (XGBoost), Logistic Regression (LR), and Adaptive Boosting (AdaBoost) using metrics such as Area Under the Receiver Operating Characteristic Curve (AUC-ROC) score, accuracy, sensitivity, specificity, and F1 score. SHAP (SHapley Additive exPlanations) analysis was used to interpret predictions.
Results The GBT model achieved the best AUC-ROC scores of 0.809, 0.821, 0.822, 0.808, and 0.833 for 1-year, 2-year, 3-year, 4-year, and 5-year prediction windows, respectively. The SHAP analysis highlighted key risk factors for ADRD, including depressive disorder, heart disease, higher age, headache, anxiety, and insomnia.
Conclusion This study demonstrates the potential of ML models using EHR data for early ADRD prediction, enabling timely interventions to delay progression and improve outcomes. These findings offer insights for future research and proactive care strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially funded by the University of Missouri.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of [University of Missouri, USA] gave ethical approval for this work under protocol number [IRB #2095682 MU]
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
